532

Gülpinar Ö[1], Haliloglu A H[2], Gökce M I[1], Arikan N[1]
1. *Ankara University Faculty Of Medicine Department Of Urology,* ***2.*** *Ufuk Universtiy Faculty Of Medicine Department Of Urology*

INSTALLATION OF HYALURONAN VIA ELECTROMOTIVE DRUG ADMINISTRATION CAN IMPROVE THE EFFICACY OF THE TREATMENT IN PATIENTS WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME: A RANDOMIZED PROSPECTIVE STUDY

Hypothesis / aims of study
In the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) intravesical hyaluronan application is an accepted treatment. In this randomized prospective study it is aimed to identify whether installating the hyaluronan with EMDA can increase the tissue uptake and imporve the efficacy.

Study design, materials and methods
The data of 31 patients who had been diagnosed with BPS/IC between 2004–2005 were examined. The patients were randomized to two groups, patients in group A received hyaluronan directly with a catheter and patients in group B received with EMDA. The patients were followed for 24 months and two groups were compared at certain time intervals.

Results
There were 6 males and 25 females. The two groups were similar for baseline parameters and efiicacy of treatment with EMDA was better at monyh 6 and 12. The difference between the two groups was not significant at month 1 and 24. Also treatment with EMDA, positive KCl test and pretreatment voiding frequency> 17 were found to be associated with higher response rates

Concluding message
Hyaluronan installation is an effective GAG substition therapy in patients with BPS/IC. To installate HA via EMDA can improve the efficacy of the treatment, however lack of the long term efficacy is the major problem of this GAG substition therapy.

Parameter	Group A (n=15)	Group B (n=16)	P value
Age (mean ± SD)	43,5 ± 4,2	42,8 ± 4,0	>0.05
Voiding frequency (/day)	18.3 ± 5.3	18.0 ± 4,9	
Nocturia (/night)	4.1 ± 1.1	3.9 ± 1.1	
Mean voided volume (ml)	147± 34,2	155± 40,3	
VAS	6.7 ± 1,2	6.8± 1.4	
Symptom score (0-20)	15.8 ± 2,3	15.6 ± 2,3	
Problem score (0-16)	13.1 ± 1,9	13.8 ± 2.0	
(+) KCl test (%)	40.0	43.7	

Table 1

Disclosures
Funding: no disclosures **Clinical Trial:** Yes **Public Registry:** No **RCT:** Yes **Subjects:** HUMAN **Ethics not Req'd:** the study is established under routine investigation protocols of our depertment and all participants signed the informed consent form. **Helsinki:** Yes **Informed Consent:** Yes